HAE remains on track, but ATTR safety findings temper the update

The headline HAE success is largely already known. The 87% attack reduction, 62% attack-free rate, favorable safety profile, and statistically significant Phase 3 HAELO results were disclosed in April and expanded in June, so this filing mainly confirms—not newly creates—the lonvo-z value case. The company still expects FDA BLA acceptance in the second half of 2026 and a U.S. launch in the first half of 2027 (HAE program update).

The quarterly numbers were mixed, with a large revenue shortfall offset by a modest EPS beat. Collaboration revenue fell to $7.7 million from $14.2 million and was well below the published consensus of roughly $15.1 million, primarily because Regeneron revenue declined. The $(0.80) per-share loss was slightly better than the roughly $(0.86) expectation, but that benefit is less important than the sharp revenue miss and does not change the company’s pre-commercial economics (Income Statement).

The most important new information is an ATTR safety risk that remains unresolved. A genomic review of more than 600 samples linked the highest liver transaminase elevations with one HLA allele, prompting HLA genotyping for current and future Phase 3 participants. Enrollment has resumed and MAGNITUDE-2 remains on track for completion in the second half of 2026, but the finding adds a new screening and regulatory issue to nex-z’s development path (Nex-z program update).

The balance sheet reduces near-term financing pressure, but mostly reflects the April capital raise. Cash increased to $628.4 million after approximately $195 million of net offering proceeds, and management says resources should fund operations into at least 2028, including beyond the planned lonvo-z launch. That is supportive, but it is not a new commercial milestone and comes with the usual dilution from the equity financing (Cash Position).

Net read: the filing preserves the lonvo-z launch story but adds enough ATTR uncertainty and revenue weakness to prevent a clean positive surprise. The HAE program is advancing on schedule, while the fresh HLA finding creates a meaningful—though not yet clearly program-threatening—risk around nex-z. With the strongest HAE data already public and no upgraded timeline or new financial upside, the overall update lands as mixed versus expectations.